A unique full-cycle influenza vaccine production using exclusive incubation technologies has been launched on the basis of the Saint Petersburg Scientific Research Institute of Vaccines and Serums of the FMBA (SPbSRIVS) in the Krasnoe Selo district of Saint Petersburg. The ceremony was opened by the Minister of Health of the Russian Federation Veronika Skvortsova: “2014 has become a milestone when our institute entered the new historical era of introduction of new biomedical and pharmaceutical technologies. The world's best technologies for the immunobiological production have been introduced, which makes it possible to obtain really safe immunological products that form a long-lasting immunity even against such antigens as the influenza virus, for at least 4-6 months after immunization.”
The Minister highly appreciated the work of the enterprise: “You have developed unique pharmaceutical products that we all may be rightfully proud of: the world’s best drug against highly pathogenic influenza, drugs against seasonal influenza, and various forms of influenza vaccines.” The opening ceremony was also attended by Deputy Minister of Industry and Trade of the Russian Federation Sergey Tsyb, Head of FMBA of Russia Vladimir Uiba, Director of the FSUE SPbSRIVS FMBA Viktor Trukhin, General Director of Microgen Scientific Research Enterprise Pyotr Kanygin, and other leading representatives of the medical community. In just six months, the antibacterial medication enterprise managed to reconstruct its production facilities. “The enterprise is now undergoing the full cycle of validation, it is already working, and we have something to show,” said Viktor Trukhin, director of the FSUE SPbSRIVS FMBA. Head of FMBA of Russia Vladimir Uiba pointed out that the SPbSRIVS is actively involved in the campaign for substitution of imported pharmaceuticals with domestic high-tech equivalents developed by Russian scientists jointly with foreign colleagues.
“The most important thing is that you are promoting Russia on the world market with high-quality pharmaceuticals, while also saving people from the influenza that affects millions of people with a high mortality rate.” Deputy Minister of Industry and Trade of the Russian Federation Sergei Tsyb stated that by launching its modernized production, the SPbSRIVS makes “a valuable contribution to the national program for the development of the pharmaceutical and medical industries in the Russian Federation.” He pledged that the Ministry of Trade would continue to actively support all the initiatives of the Federal Medical and Biologic Agency regarding the large-scale projects aimed at modernization of manufacturing sites, the construction of high-tech production facilities and those for the immunobiological production.
